These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2010 related items for PubMed ID: 15809451
1. International staging system for multiple myeloma. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. J Clin Oncol; 2005 May 20; 23(15):3412-20. PubMed ID: 15809451 [Abstract] [Full Text] [Related]
2. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Perosa F, Minoia C, Favoino E, Prete M, Dammacco F. Blood Cells Mol Dis; 2009 May 20; 42(1):71-6. PubMed ID: 18996035 [Abstract] [Full Text] [Related]
3. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases]. Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J. Ai Zheng; 2006 Apr 20; 25(4):461-4. PubMed ID: 16613681 [Abstract] [Full Text] [Related]
4. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system]. Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H. Rev Med Chil; 2008 Jan 20; 136(1):7-12. PubMed ID: 18483648 [Abstract] [Full Text] [Related]
5. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients]. Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG. Zhonghua Xue Ye Xue Za Zhi; 2008 Apr 20; 29(4):217-21. PubMed ID: 18843972 [Abstract] [Full Text] [Related]
6. Prognostic factors and staging systems of multiple myeloma: Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J. Chin Med J (Engl); 2007 Oct 05; 120(19):1655-8. PubMed ID: 17935664 [Abstract] [Full Text] [Related]
7. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V. Neoplasma; 2006 Oct 05; 53(4):277-84. PubMed ID: 16830053 [Abstract] [Full Text] [Related]
8. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Cancer; 2010 Jan 01; 116(1):84-92. PubMed ID: 19862816 [Abstract] [Full Text] [Related]
9. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Gastinne T, Leleu X, Duhamel A, Moreau AS, Franck G, Andrieux J, Lai JL, Coiteux V, Yakoub-Agha I, Bauters F, Harousseau JL, Zandecki M, Facon T, Intergroupe Francophone du Myelome (IFM). Eur J Haematol; 2007 Oct 01; 79(4):297-304. PubMed ID: 17692103 [Abstract] [Full Text] [Related]
13. [Clinical study of multiple myeloma: a report of 182 cases]. Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ. Zhonghua Yi Xue Za Zhi; 2010 Apr 13; 90(14):972-7. PubMed ID: 20646647 [Abstract] [Full Text] [Related]
15. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. Scudla V, Budíková M, Fischerová E, Zadrazil J, Indrák K. Acta Univ Palacki Olomuc Fac Med; 1991 Apr 13; 130():201-12. PubMed ID: 1838869 [Abstract] [Full Text] [Related]
16. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy]. Pertuiset E, Chevret S, Lioté F, Delauche MC, Bardin T, Dryll A, Kuntz D. Ann Med Interne (Paris); 1992 Apr 13; 143(8):519-24. PubMed ID: 1303595 [Abstract] [Full Text] [Related]
17. Analysis of criteria in staging in multiple myeloma. Pennec Y, Mottier D, Youinou P, Asselain B, Miossec P, Le Goff P, Le Prise PY, Le Menn G. Haematologia (Budap); 1982 Apr 13; 15(2):221-6. PubMed ID: 7160667 [Abstract] [Full Text] [Related]
18. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M. Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696 [Abstract] [Full Text] [Related]
19. Multiple myeloma in elderly patients: prognostic factors and outcome. Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, Grigoraki V, Anagnostopoulos N, Economopoulos T, Maniatis A, Dimopoulos MA. Eur J Haematol; 2005 Nov 15; 75(5):370-5. PubMed ID: 16191085 [Abstract] [Full Text] [Related]
20. [Classification, staging and prognostic indices for multiple myeloma]. Hotta T. Nihon Rinsho; 2007 Dec 15; 65(12):2161-6. PubMed ID: 18069256 [Abstract] [Full Text] [Related] Page: [Next] [New Search]